Maintenance of remission in patients with ulcerative colitis with once- or twice-daily MMX™ mesalazine: results of an international multicentre randomised trial

Introduction: MMX Multi Matrix System® (MMX) mesalazine (MEZAVANT™; MEZAVANT™ XL [UK and Ireland]; LIALDA™ [USA]) is a once daily, high-strength (1.2g/tablet), prolonged-release formulation of 5-aminosalicylic acid (5-ASA). In this study, the safety and efficacy of MMX mesalazine when dosed once or twice daily, was evaluated in patients whose ulcerative colitis (UC) was in remission. Methods: Patients enrolled into this randomised, multicentre, open-label, long-term trial (SPD476–303) had previously had active mild-to-moderate UC and had achieved strictly-defined clinical and endoscopic remission (UC disease act…